Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Phenylbutazone→

Phenylbutazone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
50-33-9
Molecular formula
C19H20N2O2
Molecular weight
308.3743 g/mol
Drug class
Non-steroidal anti-inflammatory drug (NSAID)pyrazolidinedione derivative
Mechanism of action
Inhibits cyclo-oxygenase-mediated prostaglandin synthesis, reducing inflammatory mediators and producing anti-inflammatory, analgesic and antipyretic effects. This is a class-level pharmacological description; exact clinical use is restricted by species and product authorisation.
Indications / reported uses
  • Veterinary use: relief of inflammatory conditions associated with the musculoskeletal system in dogs and horses under applicable veterinary authorisations. Certain equine oral formulations are not for use in horses intended for human consumption. It is not a general human therapeutic indication.

Sources: US FDA Animal Drugs at FDA — Phenylbutazone boluses, horses only · US eCFR 21 CFR 520.1720e — Phenylbutazone powder (horses) · US eCFR 21 CFR 522.1720 — Phenylbutazone injectable (dogs and horses) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Phenylbutazone Environmental Risk Assessment (ERA) (the Phenylbutazone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.